IP Library › Granted Patent US 12,402,884
Granted Patent B2
US 12,402,884 · App. 16/758,820 · Granted Sep 2, 2025

Systems and methods for selectively occluding the superior vena cava for treating heart conditions

Inventors: Navin K. Kapur (Hanover, MA); Richard H. Karas (Franklin, MA)
Assignee: Tufts Medical Center, Inc.
A61B17/12036A61B17/12045A61B17/12109A61B17/12136A61M25/10185A61M60/135A61M60/161A61M60/174A61M60/178A61M60/216A61M60/289A61M60/295A61M60/508A61M60/839A61M60/843A61B2017/00557A61M2025/1052A61M2205/3331
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,402,884
App. No.
16/758,820
Granted
Sep 2, 2025
Kind
B2
Abstract

Systems and methods and devices are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Claims (32)

1. A system for providing improvement in cardiorenal function for a patient, the system comprising:

a catheter having a proximal end and a distal region, the catheter configured for intravascular placement so that the distal region is disposed in a superior vena cava (SVC) of the patient;

a flow limiting element disposed on the distal region of the catheter, the flow limiting element sized and shaped to fully occlude the SVC and configured to be selectively actuated to fully occlude the SVC; and

a controller configured to be operatively coupled to the catheter, the controller comprising instructions that, when executed by one or more processors of the controller, cause the controller to intermittently actuate the flow limiting element to fully occlude the SVC for a first predetermined time interval spanning multiple cardiac cycles and to contract for a second predetermined time interval spanning multiple cardiac cycles to create a negative pressure sink in a right atrium of the patient sufficient to accelerate flow from a renal vein, thereby enhancing renal decongestion and promoting blood flow across a kidney of the patient,

wherein the first predetermined time interval is at least one minute and at least five times greater than the second predetermined time interval.

2. The system of claim 1 , further comprising:

a first pressure sensor disposed on the catheter proximal to the flow limiting element, the first pressure sensor outputting a first pressure signal; and

a second pressure sensor disposed on the catheter and distal to the flow limiting element, the second pressure sensor outputting a second pressure signal,

wherein the controller is configured to generate a first signal corresponding to a difference between the first pressure signal and the second pressure signal, the first signal indicative of a degree of occlusion of the flow limiting element.

3. The system of claim 2 , wherein the second pressure sensor is positioned between an azygos vein occlusion balloon and the SVC occlusion balloon, the system further comprising a third pressure sensor disposed on the catheter distal to the azygos vein occlusion balloon, the third pressure sensor configured to output a third pressure signal and the controller is configured to generate a second signal corresponding to a difference between the second pressure signal and the third pressure signal, the second signal indicative of a degree of occlusion of the azygos vein.

4. The system of claim 2 , wherein the controller is configured to use the first signal to determine when to actuate the flow limiting element to fully occlude the SVC and when to cease actuation of the flow limiting element.

5. The system of claim 1 , further comprising an azygos vein occlusion balloon disposed on the catheter proximal to the flow limiting element, wherein the flow limiting element is an SVC occlusion balloon.

6. The system of claim 5 , wherein the azygos vein occlusion balloon is configured to be selectively actuated to at least partially occlude an azygos vein of the patient.

7. The system of claim 6 , wherein the azygos vein occlusion balloon and the SVC occlusion balloon are independently actuated.

8. The system of claim 1 , wherein the controller is configured for implantation.

9. The system of claim 1 , wherein the flow limiting element is an SVC occlusion balloon.

10. The system of claim 1 , wherein the first predetermined time interval is 4-6 minutes and the second predetermined time interval is 1-30 seconds.

11. The system of claim 1 , wherein the flow limiting element comprises an inflatable cylindrical balloon having a relief valve coupled to the inflatable cylindrical balloon, and wherein the relief valve has an open and closed position.

12. The system of claim 11 , wherein the relief valve is configured to open at a pressure between 30-60 mmHg to permit fluid to flow through the SVC to a right atrium of the patient.

13. The system of claim 11 , wherein the relief valve is a binary valve configured to rapidly transform to an open position upon application of a pressure force beyond a certain threshold.

14. The system of claim 11 , wherein the relief valve is a gradual valve configured to gradually transform to an open position as a pressure force applied to the relief valve increases.

15. The system of claim 1 , wherein the system is configured for use in combination with a ventricular assist device (VAD) for improving efficiency and functionality of the VAD.

16. The system of claim 1 , wherein the controller is configured to intermittently actuate the flow limiting element to reduce cardiac preload during the interval sufficiently to improve cardiac performance as measured by at least one of: reduced cardiac filling pressures, increased left ventricular relaxation, increased left ventricular capacitance, increased left ventricular stroke volume, increased lusitropy, reduced left ventricular stiffness, or reduced cardiac strain.

17. The system of claim 1 , wherein the first predetermined time interval is at least ten times greater than the second predetermined time interval.

18. The system of claim 17 , wherein the first predetermined time interval is 4-6 minutes and the second predetermined time interval is 1-10 seconds.

19. A method for providing improvement in cardiorenal function for a patient, the method comprising:

intravascularly placing a flow limiting element disposed on a distal region of a catheter into a superior vena cava (SVC) of the patient; and

intermittently actuating the flow limiting element responsive to instructions programmed in a controller to expand the flow limiting element to fully occlude the SVC for a first predetermined time interval spanning multiple cardiac cycles and to contract for a second predetermined time interval spanning multiple cardiac cycles, wherein the first predetermined time interval is at least one minute and at least five times greater than the second predetermined time interval,

wherein intermittently actuating the flow limiting element creates a negative pressure sink in a right atrium of the patient sufficient to accelerate flow from a renal vein, thereby enhancing renal decongestion and promoting blood flow across a kidney of the patient.

20. The method of claim 19 , wherein the first predetermined time interval is 4-6 minutes and the second predetermined time interval is 1-30 seconds.

21. The method of claim 19 , wherein intermittently actuating the flow limiting element is done while using a ventricular assist device (VAD) for improving efficiency and functionality of the VAD.

22. The method of claim 19 , wherein the flow limiting element is an SVC occlusion balloon.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2020
From: KAPUR, NAVIN K.; KARAS, RICHARD H.
To: TUFTS MEDICAL CENTER, INC.
Reel/Frame 052495/0274 →
Continuity (3)
Provisional Application 62642569 · Mar 13, 2018
Provisional Application 62576529 · Oct 24, 2017
Related Publication 20210177425A1 · Jun 17, 2021
References Cited (113)
US 4546759A · Solar · 1985 [cited by applicant]
US 4576181A · Wallace et al. · 1986 [cited by applicant]
US 4610256A · Wallace · 1986 [cited by applicant]
US 4846787A · Aall-Flood et al. · 1989 [cited by applicant]
US 4949723A · Wallace et al. · 1990 [cited by applicant]
US 5021046A · Wallace · 1991 [cited by applicant]
US 5097840A · Wallace et al. · 1992 [cited by applicant]
US 5330451A · Gabbay · 1994 [cited by applicant]
US 5458574A · MacHold et al. · 1995 [cited by applicant]
US 6146354A · Beil · 2000 [cited by applicant]
US 6485500B1 · Kokish · 2002 [cited by examiner]
US 6726651B1 · Robinson et al. · 2004 [cited by applicant]
US 6790043B2 · Aboud · 2004 [cited by applicant]
US 6843779B1 · Andrysiak et al. · 2005 [cited by applicant]
US 7476200B2 · Tal · 2009 [cited by applicant]
US 7896840B2 · Spencer et al. · 2011 [cited by applicant]
US 7909794B2 · Briscoe et al. · 2011 [cited by applicant]
US 7909844B2 · Alkhatib et al. · 2011 [cited by applicant]
US 7914643B2 · Simpson · 2011 [cited by applicant]
US 7951259B2 · Duchamp et al. · 2011 [cited by applicant]
US 7959667B2 · Ta et al. · 2011 [cited by applicant]
US 7967781B2 · Simpson et al. · 2011 [cited by applicant]
US 7972299B2 · Carter et al. · 2011 [cited by applicant]
US 8449565B2 · Duhay · 2013 [cited by applicant]
US 8646325B2 · Hoem et al. · 2014 [cited by applicant]
US 8679052B2 · Bellantone · 2014 [cited by applicant]
US 8876850B1 · Vollmers et al. · 2014 [cited by applicant]
US 8968239B2 · Herrera · 2015 [cited by applicant]
US 9393384B1 · Kapur · 2016 [cited by examiner]
US 9878080B2 · Kaiser et al. · 2018 [cited by applicant]
US 9901722B2 · Nitzan et al. · 2018 [cited by applicant]
US 10279152B2 · Kapur et al. · 2019 [cited by applicant]
US 10639460B2 · Nitzan et al. · 2020 [cited by applicant]
US 10653871B2 · Nitzan et al. · 2020 [cited by applicant]
US 10758715B2 · Kapur et al. · 2020 [cited by applicant]
US 10926069B2 · Nitzan et al. · 2021 [cited by applicant]
US 20030186203A1 · Aboud · 2003 [cited by applicant]
US 20040022640A1 · Siess et al. · 2004 [cited by applicant]
US 20040064090A1 · Keren et al. · 2004 [cited by applicant]
US 20040167376A1 · Peters · 2004 [cited by examiner]
US 20050015048A1 · Chiu · 2005 [cited by examiner]
US 20060064059A1 · Gelfand · 2006 [cited by examiner]
US 20060206029A1 · Yair · 2006 [cited by applicant]
US 20080294070A1 · Kinori · 2008 [cited by applicant]
US 20090131785A1 · Lee et al. · 2009 [cited by applicant]
US 20100318114A1 · Pranevicius · 2010 [cited by examiner]
US 20100331876A1 · Cedeno · 2010 [cited by applicant]
US 20110202084A1 · Hoem et al. · 2011 [cited by applicant]
US 20110282274A1 · Fulton, III · 2011 [cited by applicant]
US 20110295302A1 · Mohl · 2011 [cited by examiner]
US 20120029466A1 · Callaghan et al. · 2012 [cited by applicant]
US 20130023909A1 · Duhay · 2013 [cited by examiner]
US 20150201944A1 · Starnes · 2015 [cited by examiner]
US 20150223707A1 · Ludoph · 2015 [cited by applicant]
US 20170049946A1 · Kapur et al. · 2017 [cited by applicant]
US 20180000488A1 · Hu · 2018 [cited by examiner]
US 20180243541A1 · Kapur et al. · 2018 [cited by applicant]
US 20190070348A1 · Frost · 2019 [cited by applicant]
US 20190126014A1 · Kapur et al. · 2019 [cited by applicant]
US 20190255302A1 · Kapur et al. · 2019 [cited by applicant]
US 20200038566A1 · Johnson et al. · 2020 [cited by applicant]
US 20210077792A1 · Kapur et al. · 2021 [cited by applicant]
EP 2353501A1 · 2011 [cited by applicant]
EP 2353503A1 · 2011 [cited by applicant]
WO WO9300037A1 · 1993 [cited by applicant]
WO WO2004073796A2 · 2004 [cited by applicant]
WO WO2013061281A1 · 2013 [cited by applicant]
WO WO2015009028A1 · 2015 [cited by applicant]
WO WO2015109028A1 · 2015 [cited by applicant]
WO WO2017031068A1 · 2017 [cited by applicant]
WO WO2017081561A1 · 2017 [cited by applicant]
WO WO2019083989A1 · 2019 [cited by applicant]
WO WO2019140073A1 · 2019 [cited by applicant]
WO WO2020061143A1 · 2020 [cited by applicant]
WO WO2020097428A1 · 2020 [cited by applicant]
Herrera, et al., First Percutaneous Transluminal Caval Flow Restriction in a Patient With Congestive Heart Failure, Abstract No. TCT-428, New Devices and Innovation, www.jacctctabstracts 2014.com, vol. 64/11/Suppl B, Se… [cited by applicant]
ISR & Written Opinion dated Oct. 18, 2016 in Int'l PCT Patent Application Serial No. PCT/US2016/047055 (0210). [cited by applicant]
ISR & Written Opinion dated Jan. 28, 2019 in Int'l PCT Patent Application Serial No. PCT/US2018/057085 (0310). [cited by applicant]
Kappagoda, et al., Effect of Stimulating Right Atrial Receptors on Urine Floe in the Dog, J. Physiol, 235:493-502 (1973). [cited by applicant]
Kapur, et al., First-in-human experience with occlusion of the superior vena cava to reduce cardiac filling pressures in congestive heart failure, Catheter Cardiovasc. Interv., 93:1205-1210 (2019). [cited by applicant]
Kapur, et al., Intermittent Occlusion of the Superior Vena Cava Reduces Cardiac Filling Pressures in Preclinical Models of Heart Failure, Journal of Cardiovascular Translational Research, published on: Nov. 26, 2019, ht… [cited by applicant]
Rachapalli, et al., Superior Vena Cava Syndrome: Role of the Interventionalist, Canadian Association of Radiologists Journal, 65:168-176 (2014). [cited by applicant]
Tzifa, et al., Endovascular Treatment for Superior Vena Cava Occlusion or Obstruction in a Pediatric and Young Adult Population, A 22-Year Experience, Journal of the American College of Cardiology, 49(9):1003-1009 (2007… [cited by applicant]
Atherton, et al., Diastolic Ventricular Interaction in Chronic Heart Failure, [cited by applicant]
Hansen, et al., Veno-occlusive unloading of the heart reduces infarct size in experimental ischemia-reperfusion, [cited by applicant]
International Search Report & Written Opinion dated Feb. 18, 2021 in Int'l PCT Patent Appl. Serial No. PCT/US2020/061386 (0410). [cited by applicant]
Ishiguchi, et al., Endovascular Stent-Graft Deployment: Temporary Vena Caval Occlusion with Balloons to Control Aortic Blood Flow—Experimental Canine Study and Initial Clinical Experience, Radiology, 215:(2):594-599 (20… [cited by applicant]
Kaiser, et al., First-in-Human Experience of Mechanical Preload Control in Patients With HFpEF During Exercise, [cited by applicant]
Kass, et al., Use of a conductance (volume) catheter and transient inferior vena caval occlusion for rapid determination of pressure-volume relationships in man, [cited by applicant]
Lee et al., Partial right atrial inflow occlusion for controlled systemic hypotension during thoracic endovascular aortic repair, [cited by applicant]
Mehta, M.D., Manish, Compliant Occlusion Balloons—Use of complaint occlusion balloons during EVAR for AAA rupture, insert to [cited by applicant]
Rodrigues, et al., Effect of baroreceptor denervation on the autonomic control of arterial pressure in conscious mice, [cited by applicant]
Rosenblum, et al., Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure, [cited by applicant]
Ross, et al., Studies on Starling's Law of the Heart, IX. The Effects of Impeding Venous Return on Performance of the Normal and Failing Human Left Ventricle, [cited by applicant]
Van Fossen, et al., Safety and efficacy of inferior vena caval occlusion to rapidly alter ventricular loading conditions in idiopathic dilated cardiomyopathy, The American Journal of Cardiology, 59(9):937-942 (1987). [cited by applicant]
Bannon, et al., Anatomic Considerations for Central Venous Cannulation, 4 Rick Management and Healthcare Policy, 4:27-39 (2011). [cited by applicant]
Difference Between Superior and Inferior Vena Cava, Pediaa (Aug. 28, 2018), https://pediaa.com/difference-between-superior-and-inferior-vena-cava/. [cited by applicant]
Extended EP Search Report dated Oct. 20, 2021 in EP Patent Application Serial No. 21177661.2 (0331). [cited by applicant]
Moscucci, M., Grossman & Baim's Cardiac Catheterization, Angiography, and Intervention, 8th Edition, 2014. [cited by applicant]
Shimizu, et al., Embolization of a Fractured Central Venous Catheter Placed Using the Internal Jugular Approach, International Journal of Surgery Case Reports, 5(5):219-221 (Jan. 2014). [cited by applicant]
Swan, et al., Catheterization of the Heart in Man With Use of a Flow-Directed Balloon-Tipped Catheter, New England Journal of Medicine, 283(9):447-451 (Aug. 1970). [cited by applicant]
Tucker, et al., Anatomy, Abdomen and Pelvis, Inferior Vena Cava, Jul. 27, 2021, available at https://www.ncbi.nlm.nih.gov/books/NBK482353/. [cited by applicant]
Yancy, et al., 2013 ACCF/AHA Guideline for the Management of Heart Failure—A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128:e240-e3… [cited by applicant]
Bilecen, et al., MR Angiography With Venous Compression, Radiology, 233(2):617-619 (Nov. 2004). [cited by applicant]
Delis, et al., Effect of Posture on Popliteal Artery Hemodynamics, 135(3):265-269 (Mar. 2000). [cited by applicant]
Low, Phillip A., “Venoarteriolar Reflex,” Primer on the Autonomic Nervous System, Second Edition, Chapter 38, pp. 152-153 (2004). [cited by applicant]
Mork, et al., Impaired Neurogenic Control of Skin Perfusion in Erythromelalgia, Journal of Investigative Dermatology, 118(4):699-703 (Apr. 2002). [cited by applicant]
International Search Report & Written Opinion dated Aug. 23, 2023 in Int'l PCT Patent Appl. Serial No. PCT/US2023/024440 (0510). [cited by applicant]
U.S. Appl. No. 14/828,429 / U.S. Pat. No. 9,393,384, filed Aug. 17, 2015 / Jul. 19, 2016. [cited by applicant]
U.S. Appl. No. 15/203,437 / U.S. Pat. No. 10,279,152, filed Jul. 6, 2016 / May 7, 2019. [cited by applicant]
U.S. Appl. No. 15/753,300, filed Aug. 15, 2016. [cited by applicant]
U.S. Appl. No. 16/168,357, filed Oct. 23, 2018. [cited by applicant]
U.S. Appl. No. 16/402,194, filed May 2, 2019. [cited by applicant]
Cited By (1)
US 12,708,370